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LETTER TO THE EDITOR  Prevention and treatment of obesity in coronary patients 315
with severe obesity and concomitant type 2 dia‑
betes mellitus in the absence of pre ‑existing CAD 
has been shown to reduce the 5 ‑year risk for in‑
cident CAD, macrovascular composite outcome 
and all ‑cause death compared with the nonsur‑
gical group.4 In a more recent retrospective co‑
hort study, also enrolling subjects with type 2 
diabetes mellitus and morbid obesity (including, 
however, participants with pre ‑existing CAD), it 
was demonstrated that metabolic surgery is as‑
sociated with a significant decrease in the 8 ‑year 
risk for the primary composite cardiovascular 
outcome and for CAD events, as well, compared 
with nonsurgical management.5
Collectively, it seems that we have, for the first 
time, treatment options for optimal manage‑
ment of obese patients with concomitant CAD, 
in order to decrease cardiovascular morbidity 
and mortality and all ‑cause mortality. It would 
be interesting to document prospectively in sur‑
veys similar to that conducted by Kozieł et al1 
whether current knowledge affects physicians’ 
treatment preferences and the impact of such in‑
terventions on the quality of life and outcomes 
of specific interest of affected patients. In addi‑
tion, it would be valuable to know whether there 
is a gender ‑specific phenotype and the effect of 
applied treatment on disease course and over‑
all prognosis.
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To the editor We have read with great interest 
the results of the retrospective analysis by Kozieł 
et al,1 showing that the relative frequency of cen‑
tral obesity significantly increased among patients 
with established coronary artery disease (CAD) 
over an observation period of 20 years. Notably, 
as the researchers state, the results were signif‑
icant only for male participants, while the im‑
pact of dysglycemia was also greater over time.1 
As obesity represents an independent, strong car‑
diovascular risk factor, with increasing prevalence, 
especially in the Western world, it is undoubted 
that we need appropriate treatment options, be‑
sides lifestyle modification, including pharmaco‑
logic intervention and bariatric surgery in more 
severe cases.2
It seems that, especially as the prevalence of 
dysglycemia is high among obese patients with 
concomitant CAD, novel antidiabetic agents, 
namely glucagon ‑like peptide ‑1 receptor agonists 
(GLP ‑1RAs) and sodium ‑glucose co ‑transporter ‑2 
(SGLT ‑2) inhibitors can play a catalytic role in 
the management of such patients, for the reduc‑
tion of body weight and visceral adiposity, along 
with the optimal control of several other cardio‑
vascular risk factors. Both drug classes are asso‑
ciated with significant decrease in the risk for 
myocardial infarction and cardiovascular death, 
as demonstrated in a recent meta ‑analysis of 
the first hallmark cardiovascular outcome trials 
in the field.3 Therefore, novel antidiabetic agents 
could be the ideal pharmacologic intervention 
for obese patients with concomitant CAD, even 
in the absence of diabetes mellitus, as more re‑
cent randomized controlled trials have estab‑
lished their cardiovascular efficacy also in non‑
diabetic individuals.
Bariatric surgery is indicated for patients with 
body mass index (BMI) greater than 40 kg/m2, or 
35 kg/m2 for those with comorbidities. A ques‑
tion that arises is whether such an intervention 
is safe for patients with cardiovascular comorbid‑
ities and if the expected result can alter the over‑
all prognosis. Recently published real ‑world data 
are really promising. Bariatric surgery in patients 
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over the life course after the event seems to be 
essential to prevent the deterioration of the di‑
rect effects of the program.
We agree with Patoulias et al1 that the use of 
new drugs with weight loss potential and bariat‑
ric surgery is likely to increase in the future. How‑
ever, it is questionable whether such an increase 
should be considered as a success of a health care 
system.
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 Authors’ reply We thank Patoulias et al1 for their 
interest in our recent paper on the ongoing pan‑
demic of obesity in patients with coronary ar‑
tery disease.2 We fully agree that obesity repre‑
sents an independent, strong cardiovascular risk 
factor with increasing prevalence, and appropri‑
ate treatment options are needed. Moreover, we 
agree that new pharmacologic treatments which 
have become available recently, as well as modern 
bariatric surgery constitute valuable options for 
some patients. However, we deeply believe that 
education and lifestyle modification, including 
intervention on diet and physical activity in par‑
ticular, remain the most important, and drugs or 
surgery should not be considered as a panacea 
for increasing prevalence of obesity, even if their 
use, as correctly pointed out by Patoulias et al,1 is 
related to improved prognosis. Indeed, we can‑
not imagine long ‑term high ‑level efficacy of any 
pharmacologic or surgical treatment if it is not 
accompanied by an effective education and life‑
style modification program. Education ‑based sec‑
ondary prevention programs may improve surviv‑
al.3 Moreover, their cost ‑effectiveness is proved.4 
Unfortunately, many health systems fail to pro‑
vide education and rehabilitation programs of 
sufficient high quality for all patients with coro‑
nary artery disease.5 In addition, access to healthy 
food is limited in many countries similarly to ex‑
ercise and recreational facilities.
The current guidelines recommend rehabilita‑
tion programs for all patients with coronary artery 
disease. Such programs should not be focused on 
physical activity in a short period after the event, 
but rather should aim at modification of patients’ 
lifestyle in a longer perspective. This includes 
change of diet, regular exercising, and avoiding 
smoking, including second ‑hand smoking. Also, 
the intervention to increase adherence to pre‑
scribed therapies should be considered as impor‑
tant as lifestyle change. Finally, the sustained care 
